MAPUTO, Mozambique — Partnership will be the key to UNITAID’s new $50 million, five-year investment in increasing antimalarial treatment for pregnant women in sub-Saharan Africa.
The Transforming Intermittent Preventive Treatment for Optimal Pregnancy — or Tiptop — program will introduce community-level distribution of quality-assured sulfadoxine-pyrimethamine (SP) to 400,000 pregnant women and their babies in Mozambique, the Democratic Republic of the Congo, Nigeria, and Madagascar, and inform change in policy recommendations from the World Health Organization.
Tiptop is implemented by a partnership between Jhpiego, a nonprofit affiliated with Johns Hopkins University, and the Barcelona Institute for Global Health (ISGlobal).
In Mozambique, Devex got the inside track on how this partnership came together — and gathered advice on how to make collaboration work in global health.
About the author
Gloria PallaresGloriaspv
Gloria Pallares is a journalist reporting on sustainable development, global health and humanitarian aid from Africa and Europe. Her work has appeared in a range of publications including El Pais, Forbes, CIFOR’s Forest News and the leading media outlets in Spain via the multimedia newswire Europa Press.
